| 66.96 0.26 (0.39%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 90.08 | 1-year : | 105.99 |
| Resists | First : | 77.12 | Second : | 90.75 |
| Pivot price | 59.86 |
|||
| Supports | First : | 55.08 | Second : | 45.83 |
| MAs | MA(5) : | 64 |
MA(20) : | 59.69 |
| MA(100) : | 56.03 |
MA(250) : | 53.39 |
|
| MACD | MACD : | 1.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 34.9 |
| RSI | RSI(14): 61 |
|||
| 52-week | High : | 90.75 | Low : | 39.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ PCVX ] has closed below upper band by 14.6%. Bollinger Bands are 147.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 67.18 - 67.5 | 67.5 - 67.8 |
| Low: | 63.47 - 63.83 | 63.83 - 64.17 |
| Close: | 66.36 - 66.93 | 66.93 - 67.48 |
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Tue, 06 Oct 2026
Vaxcyte Announces Pricing of Concurrent Public Offerings of - GlobeNewswire
Tue, 06 Oct 2026
Vaxcyte: 'Strong Buy' On VAX-31 Trial Win IPD VAX-31 And Additional Readouts 1st Half 2027 - Seeking Alpha
Mon, 05 Oct 2026
Vaxcyte stock falls on $1B dual offering launch - Yahoo Finance
Mon, 05 Oct 2026
Vaxcyte, Inc. - Common Stock (Nasdaq:PCVX) Stock Quote - FinancialContent
Mon, 05 Oct 2026
Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck - Barron's
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 149 (M) |
| Shares Float | 136 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 113.4 (%) |
| Shares Short | 14,800 (K) |
| Shares Short P.Month | 14,230 (K) |
| EPS | -7.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.7 % |
| Return on Equity (ttm) | -36.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -7.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -881 (M) |
| Levered Free Cash Flow | -486 (M) |
| PE Ratio | -8.78 |
| PEG Ratio | 0 |
| Price to Book value | 3.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|